We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis is proposing to divest a small group of pharmaceutical products as a means to gain European Union (EU) approval for its acquisition of German generics company Hexal AG.
Andrx has signed a deal with Amphastar Pharmaceuticals to purchase partial U.S. marketing rights to a generic version of sanofi-aventis’ blockbuster thrombosis treatment Lovenox.
Johnson & Johnson (J&J) received approval from the Federal Trade Commission (FTC) to acquire Raleigh, N.C.-based Closure Medical, a maker of wound-healing products.
GlaxoSmithKline (GSK) plans to acquire biotechnology firm Corixa for $300 million — a move that will bolster the British drug giant’s vaccine and antigen portfolios.
Guidant shareholders overwhelmingly approved the proposed $25.4 billion sale of the Indiana-based devicemaker to Johnson & Johnson (J&J) in a special April 27 meeting.
Johnson & Johnson (J&J) has announced plans to purchase the privately held biopharmaceutical firm Peninsula Pharmaceuticals for $245 million — a move that would bolster its antibiotic pipeline.
Johnson & Johnson (J&J) this week moved to bolster its antibiotic pipeline, announcing plans to purchase privately held biopharmaceutical firm Peninsula Pharmaceuticals for $245 million.
The FTC submitted a second request to Novartis Pharmaceuticals last week for additional information about its pending acquisitions of German generic drugmaker Hexal AG and U.S. generic firm Eon Labs.
Mergers between generic and brand firms are becoming an increasingly attractive option in today’s challenging business climate, according to an industry expert, who said such partnerships can bring synergies that neither partner could achieve on its own.